Bill 119 hr 1492, also known as the Equalizing Negotiation Periods for Small-Molecule and Biologic Candidates Act, aims to amend title XI of the Social Security Act. The main goal of this bill is to ensure that the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program is equalized. Currently, there is a discrepancy in the negotiation periods for small-molecule and biologic candidates, with biologic candidates having a longer negotiation period. This bill seeks to address this imbalance by equalizing the negotiation periods for both types of candidates. By equalizing the negotiation periods, the bill aims to create a more level playing field for small-molecule and biologic candidates in the Drug Price Negotiation Program. This could potentially lead to fairer pricing for both types of drugs and ultimately benefit consumers by ensuring that they have access to affordable medications. Overall, Bill 119 hr 1492 is focused on promoting fairness and equality in the negotiation process for small-molecule and biologic candidates under the Drug Price Negotiation Program. It will be interesting to see how this bill progresses through Congress and what impact it may have on drug pricing in the future.
Bill 119 hr 1492, also known as the Equalizing Negotiation Periods for Small-Molecule and Biologic Candidates Act, aims to amend title XI of the Social Security Act. The main goal of this bill is to ensure that the negotiatio...